Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

Title[Dronabinol for supportive therapy in patients with malignant melanoma and liver metastases.] [Article in German]
Author(s)Zutt M, Hanssle H, Emmert S, Neumann C, Kretschmer L.
Journal, Volume, IssueHautarzt 2006;57(5):423-7.
Major outcome(s) A significant increase in appetite and decrease in nausea in most patients.
IndicationNausea/vomiting;Appetite loss/weight loss;Cancer;Cancer chemotherapyAbstract

BACKGROUND: Loss of appetite and nausea can reduce the quality of life of patients with malignant melanoma and liver metastases. Often established antiemetic drugs fail to bring relief. Tetrahydrocannabinol (THC, Marinol (TM)), which is the active agent of Indian hemp, has been used successfully in this situation for other malignant tumors.PATIENTS AND METHODS: We treated 7 patients with hematogenous metastatic melanoma and liver metastases suffering from extensive loss of appetite and nausea supportively with dronabinol (Marinol((R))). All of these patients had previously received standard antiemetic therapy without adequate relief. Dronabinol is a synthetic Delta-tetrahydrocannabinol. The drug was administered in capsule form. We evaluated the palliative effects of dronabinol with a special patient evaluation form, which was filled out at the beginning of the therapy and again after 4 weeks.RESULTS: The majority of patients described a significant increase in appetite and decrease in nausea. These effects remained for some weeks, but then decreased as metastases progressed and the general condition worsened. All of the patients experienced slight to moderate dizziness, but it was not sufficiently troubling to cause interruption or termination of therapy.CONCLUSION: Loss of appetite and nausea due to liver metastases of malignant melanoma can be treated in individual cases supportively with Dronabinol.

Duration (days)
Participants7 patients with hematogenous metastatic melanoma
DesignOpen study
Type of publicationMedical journal
Address of author(s)Hautklinik und Poliklinik der Georg-August-Universitat Gottingen, Germany
Full text

[Back to Overview]  [IACM Homepage]